Korsana Biosciences has secured $175 million in Series A funding to advance its innovative therapeutics for neurodegenerative diseases, co-led by Wellington Management and TCGX.
Amount Raised
$175 Million
Round Type
Series A
WalthamBiotechnologyHealthcareHealth CareTherapeuticsInvestors
Description
Korsana Biosciences, a biotechnology company focused on neurodegenerative diseases, has emerged from stealth mode with significant funding. The company raised a total of $175 million in Series A financing to further develop its lead program, KRSA-028, targeting Alzheimer’s disease. This funding will enable Korsana to enhance its proprietary THETA™ therapeutic platform as it aims to improve treatment options. The financing round saw participation from notable investors including J.P
Who to call at Korsana Biosciences, and when
A new round usually means Korsana Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Korsana Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Korsana Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Korsana Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Korsana Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansKorsana Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.